Status:
COMPLETED
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
65+ years
Phase:
PHASE3
Brief Summary
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with at least 65 years-old
- Patients with essential hypertension Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT00219167
Start Date
April 1 2005
End Date
February 1 2006
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland